Registration Dossier
Registration Dossier
Please be aware that this old REACH registration data factsheet is no longer maintained; it remains frozen as of 19th May 2023.
The new ECHA CHEM database has been released by ECHA, and it now contains all REACH registration data. There are more details on the transition of ECHA's published data to ECHA CHEM here.
Use of this information is subject to copyright laws and may require the permission of the owner of the information, as described in the ECHA Legal Notice.
EC number: 402-810-3 | CAS number: 17980-47-1 DYNASILAN BH N; DYNASILAN BSM 100 N; DYNASILAN NH 42
Endpoint summary
Administrative data
Description of key information
In an acute oral toxicity study conducted using a protocol comparable to the now deleted OECD 401 (Huntingdon Research Centre Ltd., 1987a) the LD50 for triethoxyisobutylsilane was >5000 mg/kg bw in rats. Signs of reaction to treatment observed in all rats shortly after dosing were piloerection, abnormal body carriage (hunched posture) and abnormal gait (waddling). Only piloerection persisted on Day 2. There were no other clinical signs, and recovery was complete by Day 3. There were no abnormal findings at necrospy.
In the key acute inhalation study conducted using a protocol comparable to OECD 403 and to GLP (Huntingdon Research Centre, 1990) the LC50 for a triethoxyisobutylsilane aerosol was greater than 5.88 mg/l in rats. There were signs of respiratory tract irritation, but no signs of systemic toxicity.
In an acute dermal toxicity study conducted using a protocol comparable to OECD 402 and to GLP (Huntingdon Research Centre Ltd, 1987b) the LD50 for triethoxyisobutylsilane was >2000 mg/kg bw in rats. There were no systemic effects and no signs of dermal irritation.
Key value for chemical safety assessment
Acute toxicity: via oral route
Endpoint conclusion
- Dose descriptor:
- LD50
- Value:
- 5 000 mg/kg bw
Acute toxicity: via inhalation route
Endpoint conclusion
- Dose descriptor:
- LC50
- Value:
- 5 880 mg/m³ air
Acute toxicity: via dermal route
Endpoint conclusion
- Dose descriptor:
- LD50
- Value:
- 2 000 mg/kg bw
Additional information
There are reliable acute oral, dermal and inhalation studies available for triethoxyisobutylsilane. Results from a supporting oral gavage study were in agreement with the key study results. There are no additional data for the dermal and inhalation routes.
Justification for classification or non-classification
Based on the available data triethoxyisobutylsilane is not classified for acute toxicity according to Regulation 1272/2008/EC.
Information on Registered Substances comes from registration dossiers which have been assigned a registration number. The assignment of a registration number does however not guarantee that the information in the dossier is correct or that the dossier is compliant with Regulation (EC) No 1907/2006 (the REACH Regulation). This information has not been reviewed or verified by the Agency or any other authority. The content is subject to change without prior notice.
Reproduction or further distribution of this information may be subject to copyright protection. Use of the information without obtaining the permission from the owner(s) of the respective information might violate the rights of the owner.
